Earnings summaries and quarterly performance for BIODESIX.
Executive leadership at BIODESIX.
Board of directors at BIODESIX.
Research analysts who have asked questions during BIODESIX earnings calls.
Andrew Brackmann
William Blair & Company, L.L.C.
4 questions for BDSX
Also covers: ADPT, AWH, BFLY +11 more
Thomas Flaten
Lake Street Capital Markets
4 questions for BDSX
Also covers: ACHV, AQST, ASRT +13 more
Kyle Mikson
Canaccord Genuity
3 questions for BDSX
Also covers: AKYA, CSTL, EXAS +12 more
Sung Ji Nam
Scotiabank
3 questions for BDSX
Also covers: ADPT, BNGO, CSTL +9 more
William Bonello
Craig-Hallum Capital Group
3 questions for BDSX
Also covers: CDNA, CERS, EXAS +6 more
Daniel Brennan
TD Cowen
2 questions for BDSX
Also covers: A, ADPT, AVTR +24 more
William Ruby
TD Cowen
2 questions for BDSX
Also covers: PACB, PSNL, SERA +1 more
Alex Vukasin
Canaccord Genuity - Global Capital Markets
1 question for BDSX
Also covers: GRAL
Bill Bonello
Craig-Hallum Capital Group LLC
1 question for BDSX
Also covers: GH, MYGN, SOPH +1 more
Recent press releases and 8-K filings for BDSX.
Biodesix Reports Strong Q3 2025 Revenue Growth and Raises Full-Year Guidance
BDSX
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Biodesix reported Q3 2025 total revenue of $21.8 million, marking a 20% increase year-over-year. This was supported by 16% growth in lung diagnostic testing revenue to $19.8 million and 97% growth in development services revenue to $1.9 million.
- The company achieved a gross margin of 81% in Q3 2025, an improvement of 400 basis points from the prior year. The net loss improved by 15% year-over-year to $8.7 million, and the adjusted EBITDA loss improved by 18% year-over-year to $4.6 million.
- Biodesix increased its full-year 2025 revenue guidance to $84-$86 million and expects to achieve adjusted EBITDA positivity in the fourth quarter of 2025.
- Key operational metrics include 15,700 total lung diagnostic tests delivered in Q3 2025, a 75% increase in tests ordered from primary care over Q3 2024, and an average of 85 sales reps in the field, projected to increase to 93-97 in Q4.
Nov 3, 2025, 9:30 PM
Biodesix Announces Third Quarter 2025 Results and Raises Full-Year Revenue Guidance
BDSX
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Biodesix reported Q3 2025 revenue of $21.8 million, marking a 20% increase over Q3 2024.
- The company achieved an 81% gross profit margin in Q3 2025, which is a 400-basis point improvement from the prior year comparable period.
- Biodesix raised its FY2025 total revenue guidance to $84-86 million.
- Net loss for Q3 2025 was $8.7 million, and Adjusted EBITDA was a loss of $4.6 million.
- Development Services revenue grew 97% year-over-year, and Lung Diagnostic Tests ordered in primary care increased by more than 75% compared to Q3 2024.
Nov 3, 2025, 9:02 PM
Biodesix Announces One-for-Twenty Reverse Stock Split
BDSX
Proxy Vote Outcomes
- Biodesix, Inc. announced a one-for-twenty reverse stock split of its common stock.
- The reverse stock split will become effective at 12:01 a.m. Eastern Time on Monday, September 15, 2025, with trading on a split-adjusted basis beginning the same day on the Nasdaq Global Market.
- As a result of the split, every 20 shares of pre-split common stock issued and outstanding will be automatically reclassified into one new share.
- This action will reduce the number of shares of common stock issued and outstanding from approximately 156 million to approximately 8 million.
- Stockholders who would otherwise hold a fractional share will receive a cash payment in lieu of such fractional share.
Sep 11, 2025, 12:00 PM
Biodesix Discusses Q2 Performance, Sales Force Expansion, and Pipeline Development at Canaccord Genuity Conference
BDSX
Hiring
New Projects/Investments
Revenue Acceleration/Inflection
- Biodesix is expanding its commercial focus to include primary care physicians, with 9% of Q2 2025 orders coming from this new channel. The company plans to increase its sales force from 74 reps to 85 by the end of Q3 2025 and 95 by the end of Q4 2025 to support this expansion.
- The company exited Q2 2025 with $12.5 million in biopharmaceutical revenue under contract but not yet recognized, reflecting growth in bespoke assay development and reorders.
- Biodesix is developing a joint proteomic-genomic MRD test in partnership with Memorial Sloan Kettering, which will be available for Research Use Only (RUO) by the end of 2025, but is not planned for commercialization in 2026.
- Financially, Biodesix has approximately $20 million in cash and a quarterly cash burn of $5 million to $10 million. The company aims to fuel growth, expand its sales force, and reach adjusted EBITDA breakeven.
- Biodesix reports an industry-leading gross margin of 80%.
Aug 12, 2025, 9:40 PM
Biodesix Inc. Discusses Q1 2025 Performance and Strategic Growth Initiatives
BDSX
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- Biodesix Inc. reported Q1 2025 revenue of $18,000,000, marking 21% year-over-year growth, with lung diagnostic tests growing 18% and development services 61%.
- The company maintained gross margins just under 80% and reiterated its goal to reach adjusted EBITDA breakeven by Q4 2025.
- Fiscal year 2025 revenue guidance was revised to $80,000,000 to $85,000,000.
- Biodesix plans to expand its commercial sales force to 95 representatives by year-end, focusing on pulmonology and extending reach to primary care physicians.
- The product pipeline includes four tests in development, with plans to merge risk of recurrence and MRD efforts, expand Verastrat indications, and venture into digital diagnostics.
Jul 7, 2025, 3:09 PM
Quarterly earnings call transcripts for BIODESIX.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more